Find Reports
Select Report Type
Reimbursement Review
Displaying 1301 - 1325 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Insulin lispro | Admelog | Insulin lispro | Cancelled | SE0543-000 | |||||
| Erbitux for Left Sided Metasta... | Erbitux | Cetuximab | Cancelled | PC0128-000 | |||||
| Pegfilgrastim | Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | SE0555-000 | |||
| anakinra | Kineret | anakinra | Still's disease | Withdrawn | SR0662-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| Orilissa (elagolix) | Orilissa | elagolix | Moderate to severe pain associated with endometriosis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0011-000 | |||
| CADTH Pharmaceutical Reviews U... | |||||||||
| brentuximab vedotin | Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | PC0311-000 | ||||
| daprodustat | TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | SR0762-000 | ||||
| masitinib mesylate | Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | SR0766-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| talazoparib | Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Withdrawn | PC0316-000 | ||||
| rimegepant | Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | SR0797-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| aducanumab | Aduhelm | aducanumab | Alzheimer’s disease | Withdrawn | SR0705-000 | ||||
| pembrolizumab and lenvatinib | Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | PC0271-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| tirzepatide | TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | SR0751-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| abaloparatide | TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | SR0744-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1301 - 1325 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81